I
Intensity Therapeutics
Innovative cancer treatments targeting both visible tumors and unseen micro metastases for extended patient survival
About Intensity Therapeutics
Intensity Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer treatments. Founded in 2012, the company aims to extend the lives of cancer patients while improving their quality of life. Intensity Therapeutics operates in the oncology market, targeting both visible solid tumors and unseen micro metastases, which are small cancerous cells that can spread throughout the body. The company's lead product, INT230-6, is currently undergoing human clinical trials to treat refractory solid tumor cancers. The business model revolves around the development and clinical testing of proprietary drug formulations, with revenue generated through partnerships, investments, and potential future sales of approved treatments. Intensity Therapeutics serves patients with advanced cancer, healthcare providers, and potential investors interested in supporting innovative cancer therapies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2012
- Headquarters
- Shelton, United States
- Listing
- IPO 2023
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
VCapital- BCBatterson Venture Capital
Jim Mellon- DDDeclan Doogan
- SPSalvaRx Group PLC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intensity Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intensity Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.